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Abstract 
Background: Neonatal hyperbilirubinemia is a common and 
dangerous complication that should be diagnosed as soon as possible. 
This study aimed to validate transcutaneous bilirubin in comparison 
with serum bilirubin for the detection of hyperbilirubinemiain 
neonates. 
Methods: This cross-sectional study was conductedin 280 infants with 
jaundice who were referred to Bahar Hospital in Shahroudin 2016. The 
serum bilirubin was measured by the photometric method. Three 
measurements of transcutaneous bilirubin were performed (by 
Bilichek) for each infant, and their average was recorded. The 
sensitivity and specificity of transcutaneous bilirubin measurements 
were assessed in comparison with themeasurements usinglaboratory 
methods asthegold standard using ROC analysis. 
Results: Of the 280 neonates, 153 (54.6%) were male. The mean age of 
the patients was 11.77±4.6 days. The mean bilirubin level was 
16.9±10.1 mg/dl measured usingthe BiliChekmethodand 15.3±9.5 
mg/dl using the laboratory method, and the difference was 
significant(P<0.04). The sensitivity andspecificity of the BiliChek 
measurements in neonates were 88.3% and 73.6%, respectively. 
According to the findings from the ROC curve, the cutoff pointwas 
determined to be more than 14.7 units (surface area below the curve 
(AUC)=87.5%). 
Conclusions: The results of this study showed that the accuracy 
(sensitivity and specificity) of the BiliChek device was good and can be 
used to measure the neonatal bilirubin. 
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Introduction 
Hyperbilirubinemia is one of the most common problems 
in the neonatal period, which in most cases is not complicated 
and improves without treatment.1 However, in some neonates, 
jaundice is severe and requires treatment. Brain complications 
and kernicterus are the major adverse consequences of this 
phenomena.1-2 Often, the cause of jaundice is unclear, and the 
underlying causes of jaundice are also different, including the 
incompatibility of the mother’s blood Rh with that of the baby, 
thyroid deficiency in the infant, red blood cell enzyme 
deficiency such as fauvism disease, jaundice due to lack of 
breast milk, and other reasons.3 The risk of jaundice depends on 
the weight and age of the baby and usually occurs in low birth 
weight and premature infants with lower bilirubin levels.1 
Neonatal jaundice is a common complaint, but few babies 
need medical treatment. Regardless of the cause, total serum 
bilirubin (TSB) is above the standard for that weight and age, 
and phototherapy is used to prevent serious complications, such 
askernicterus.4-5 
It is necessary to know the amount of bilirubin to treat 
neonatal jaundice appropriately, which is usually done in three 
ways: ocular, dermatological, and laboratory methodevaluation.6 
The most common goal of neonatal screening is to detect 
jaundice. The serum bilirubin measurement is not an ideal 
method because of the need for taking blood samples from the 
infant which leads to an increased risk of infection, anemia, 
pain, and stress. Also, this method is problematic, stressful, 
time-consuming, and costly.7-8 
Although the eye evaluation method is simple, it has two 
major problems. One is that it relies on the individual's 
experience and is not a precise and reliable criterion; second, 
the probable estimation of jaundice in this method is based on 
skin color and its dependent factors that can change in different 
conditions.8 This method is useful only in the early stages of 
the onset of jaundice and is not reliable in infants who have 
undergone photodynamic therapy. Also, the color of the skin, 
the color of clothing, and the light of the examination 
environment can completely overshadow the visual acuity.9 
Therefore, in recent years, noninvasive methods of 
bilirubin assessment have been proposed to reduce the need for 
blood sampling and reduce patient stress and laboratory costs. 
One of these non-invasive methods is jaundice transcutaneous 
bilirubinometry (TCB).8-9 
Bilichek devices measure the severity of jaundice based on 
the light reflected from the skin of the patient. BiliChek is 
based on the reflection of the white light waves that leak on the 
baby's skin.10-12 The optical radiation reflected from the infant's 
skin is analyzed in a BiliChek program, and the serum bilirubin 
is measured based on pre-defined patterns.10 The manufacturers 
of the BiliChek device claim that the accuracy of the device is 
optimal, and factors such as the maturity of the skin and the 
amount of melanin and hemoglobin do not affect its accuracy. 
It is also claimed that the accuracy of the BiliChek apparatus is 
very suitable for measuring bilirubin in different ethnicities and 
term and near-term neonates.12-13 According to the results of 
some studies that have reported the accuracy of the BiliChek 
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apparatus to be optimal, it may be possible to replace the 
laboratory measurement of bilirubin with it.14 Because the 
accuracy of the BiliChek is not yet exactly determined, this 
study aimed to validate the TCB for the detection of 
hyperbilirubinemia in comparison with serum bilirubin 
measurementin neonates at Bahar Hospital in Shahroud in 
2016. 
Materials and Methods  
This cross-sectional study was conducted at Bahar 
Hospital Hospital in Shahroud. The study was conducted over 
a period of 18 months (October 2015 to March 2016). This 
study included 280 infants with jaundice. Inclusion criteria: All 
infants at 36–39 weeks' gestational age, weighing between 
2500 and 3500 grams, physically healthy, and with parental 
consent to participate in the research were included. 
Infants with any blood, liver, or metabolic illness, 
admission to the Neonatal Intensive Care Unit (NICU), 
requiring exchange transfusion, and parental dissatisfaction 
were excluded. 
Ethics approval: This study has an ethics code number 
(IR.SHMU.REC.1394.143) from the Research Deputy of 
Shahroud University of Medical Sciences. The essential 
information and the objectives of the study were explained to 
the parents of the infants, and written consent was obtained for 
participation in the study. 
In this study, simultaneously with the measurement of 
serum bilirubin, the skin bilirubin level was measured using the 
BiliChek apparatus. The BiliChek device was approved by the 
US Food and Drug Administration in 2001. Also, it has gained 
standards for medical equipment.11 Serum bilirubin was 
measured in a laboratory in a standard manner (with the help of 
the Olympus Diagnostic Kit, UK). Immediately after the serum 
bilirubin testing, neonatal bilirubin measurements were 
performed using a BiliChek set (through the baby's forearm in 
the lying condition). The probe of the BiliChek was calibrated 
before each measurement, according to the manufacturer's 
instructions. Then, with the help of a button, a light was 
projected on the baby's skin, and BiliChek automatically 
analyzed the reflected waves in less than 5-minute sand read 
the average of the calculated number in either μmol/L or 
mg/dL. The forehead area used for the TCB was not exposed to 
direct sunlight and/or phototherapy. All phototherapy lights 
were turned off while the BiliChek measurement was taken. 
Care was taken to avoid skin areas with bruising, birthmarks, 
hematomas, or excessive hairiness. The gestational age, birth 
weight, postnatal age, and ethnicity were recorded. 
All the collected data from the skin and lab measurements 
of bilirubin were recorded on a computer and analyzed. The 
relationship between the TCB values and TSB measurements 
was investigated by evaluating the sensitivity, specificity, 
positive predictive value, and negative predictive value. In this 
situation, the laboratory bilirubin measurement was considered 
to be the ‘gold standard’ that determined treatment (TSB≤13 
mg/dl was considered normal, and TSB>13 mg/dl was 
considered hyperbilirubinemia).9 A ROC curve was constructed 
to investigate the relationship between the bilirubin 
measurements. The data were analyzed using SPSS software. 
Results 
Of the 280 neonates, 153 (54.6%) were male; 31.8% were in 
the age group of 11–15 days. Breastfeeding was achieved in 
69.6%, and the remaining infants were fed with synthetic milk. 
The main demographic characteristics of the study population 
are presented in table 1. The mean bilirubin level was 
16.9±10.1 mg/dl using the BiliChek device and 15.3±9.5 mg/dl 
using the laboratory method, and the difference was 
significant(P<0.04). The sensitivity of the BiliChek apparatus 
in neonates was 88.3% (95% CI: 85.5–94.0), specificity 73.6% 
(95% CI: 71.6–77.4), positive predictive value 85.5% (95% CI: 
79.4–89.5%), and negative predictive value was 57.8% (95% 
CI: 53.5–61.4). The ROC curve was used to determine the best 
cutting point and to compare the diagnostic value. In this 
method the bilirubin values of the BiliChek were compared 
with standard laboratory method in healthy infants by 
measuring the area under curve. In this way, the ROC curve 
was obtained, with the area under the curve representing the 
test detection power. According to the findings from the ROC 
curve, the cutoff point was more than 14.7 units with a surface 
area below the curve (AUC) of 87.5% (95% CI: 85.2–90.7). In 
other words, values higher than 14.7 mg/dl in the standard 
laboratory method with a sensitivity of 90.7% and specificity of 
72.8% were considered as positive tests, and lower values were 
considered as negative tests. At this point, the test has the most 
sensitivity and specificity (figure 1).  
 
Figure 1. ROC curve for transcutaneous bilirubinometry (TCB) 
Discussion 
In the present study, the sensitivity and specificity of the 
BiliChek device were found to be appropriate and acceptable. 
Table1. Demographic characteristics of the study population 
Variables Frequency (%) Mean±SD 
Sex   
- Boy 153(54.6) - 
- Girl 127(45.4) - 
Age (days) - 11.77±4.6 
Weight (gram) - 3464.64±353.64 
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The diagnosis and timely treatment of jaundice in the first few 
days of life can prevent serious complications.15-16 Problems 
with admission and hospitalization are one of the barriers to 
timely action in these patients. The basis of proper treatment in 
all these cases is the rapid and reliable detection of jaundice, 
which can be controlled by timely action. Also, it is necessary 
to ensure that the use of the new bilirubin measurement tool is 
safe and free of side effects for infants.17 There is no need for 
the alternative methods of measuring bilirubin to be as accurate 
as the standard laboratory method to the extent that high 
bilirubin is reported because the concentration of bilirubin is 
not absolute, and there are several factors affecting it. The 
decisions on therapeutic proceedings such as phototherapy are 
based on clinical judgment.18-20 The current methods of 
measuring bilirubin are dependent on venous blood sampling 
and are always accompanied by resistance and dissatisfaction 
of the families and severe crying of the newborns.21 The 
BiliChek device can be very useful due to its functional nature, 
which does not require blood sampling and does not cause any 
pain or stress to the baby and its parents. Regarding the 
accuracy of the results obtained using this device, 
comprehensive studies have not been carried out, and the 
number of studies carried out has had different results.22-24 The 
skin bilirubin measurements are significantly less than that 
obtained using the laboratory methods, but because of the 
lower complications and risks of neonatal sampling, most 
pediatricians prefer this method.25 Use of BiliChek for repeated 
measurements of bilirubin in infants cause less concern 
regarding the incidence of sampling complications.26-27 
Therefore, repeated measurements of neonatal bilirubin can be 
done with this method without the fear of blood sampling 
complications.28  
This finding was somewhat similar to the study by Knüpfer 
et al. However, they stated that the TCB measurement devices 
could only be used in specific and limited situations.29 One of 
the most important findings of this research was the cutoff-
point on the ROC curve. Using the results of the ROC curve, 
the difference between the two methods of skin and serum 
bilirubin measurement can be corrected as, in the BiliChek 
method, the amount of abnormal bilirubin was found to be 14.7 
mg/dl instead of 13 mg/dL as determined using the TSB 
method.30 Also, the lack of need for frequent blood sampling 
from infants is an important advantage of the BiliChek device 
because it reduces blood sampling complications and also 
prevents anemia.28 
To conclude, the results of the present study showed that 
the BiliChek device is a simple, reliable, and acceptable 
alternative to laboratory measurement of bilirubin. Using 
BiliChek reduces unnecessary blood sampling in newborns, 
with subsequent clinical benefits. 
The limitation of the present study was that the parents did 
not have sufficient information about the BiliChek method, 
which sometimes provoked resistance in this experiment. This 
problem was resolved by explaining about the method and 
ensuring cooperation from the parents. 
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